CTXR · Citius Pharmaceuticals, Inc. · Debt
$0.52
+0.00 (+0.00%)
At close · Oct 6
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“The Company estimates that its and Citius Oncology's collective available cash resources will be sufficient to fund our operations through November 2026. We will need to raise additional capital in the future to support our operations beyond November 2026, which raises substantial doubt about the Company's ability to continue as a going concern within one year after the date that the accompanying consolidated financial statements are issued.”View the 10-Q filed Aug 14, 2026
Market Cap
$15.38M
Shares
27.45M
Volume · Oct 5
132.55K
Avg daily vol (3M)
520.5K
Debt Profile
Reported borrowing balances, repayment dates and agreement terms, with links to the underlying filings.
Reported debt balances
Each amount keeps its reported scope. Related balance-sheet measures appear under the borrowing they describe.
| Reported balance | As of | Amount | Source |
|---|---|---|---|
| Noncurrent notes payable | 2026-06-30 | USD 6,410,161 | 10-Q filed 2026-08-14 |
| Operating lease liabilities | 2026-06-30 | USD 766,957 | 10-Q filed 2026-08-14 |
Related accounting measures — not additional borrowingCarrying amounts can reflect issuance costs or discounts. Differences between these measures are not necessarily repayments due within a year.
| |||
Instrument and agreement coverage is incomplete. Additional filings are awaiting review.
Covenants
Covenant terms have not yet been verified for this profile.
The balance figures do not establish whether covenants apply or whether the company complies with them.
Loans, facilities and notes
The instrument breakdown is not yet verified. Read the debt note in the linked report for borrowing terms and maturity conditions.